Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vytorin Efficacy in Adult Dyslipidemia
NCT00651560Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Nov 2005
- Primary completion
- Dec 2005
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, open-label, single-arm trial of Vytorin in dyslipidemia and hyperlipidemia, sponsored by Organon & Co. Primary endpoint: Hypolipidemic effect of Vytorin at 4 weeks. Started Nov 2005; status: completed.
02
Drugs
Vytorin
03
Conditions
dyslipidemiahyperlipidemia
Beyond the preview
Go deeper on NCT00651560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651560.